Rising STIs in Europe: why drug resistance makes the surge a global concern

Sexually transmitted infections are rising across Europe, and according to a Guardian analysis the trend carries a warning that reaches well beyond the continent. The concern is not only that more people are being infected but that some of the bacteria responsible are becoming harder to kill with the antibiotics that have long kept them in check. That intersection, between a rise in infections and the erosion of effective treatment, is what makes public-health specialists uneasy.

The infections in question include familiar names such as gonorrhoea, syphilis and chlamydia, alongside others that have re-emerged after years of relative quiet. Surveillance across European countries has recorded increases in several of them, a pattern attributed to a mix of factors: changes in sexual behaviour, reduced condom use, gaps in testing and treatment services, and greater awareness and detection that catches more cases than before.

What elevates the story from a regional health issue to a global one is antimicrobial resistance, often shortened to AMR. Gonorrhoea in particular has developed resistance to successive generations of antibiotics, and health agencies have repeatedly warned about strains that resist the drugs currently relied on as last-line treatment. When bacteria evolve to survive the medicines designed to eliminate them, infections that were once routine to cure can become prolonged, more transmissible and, in rare cases, untreatable with existing options.

Antimicrobial resistance is one of the defining slow-moving health threats of the era. It arises naturally as microbes evolve, but it is accelerated by the overuse and misuse of antibiotics in medicine and agriculture. Every course of antibiotics exerts selective pressure, favouring the survival of resistant organisms, and resistant strains do not respect borders. A gonorrhoea strain that develops in one region can travel with people to any other, which is why a European surge is framed as a worldwide worry.

The practical stakes are significant. Most sexually transmitted bacterial infections are curable when caught and treated promptly, and untreated cases can lead to serious complications, including infertility, pregnancy problems and increased vulnerability to other infections. If the drugs that cure them lose their power, the consequences extend from individual health to the wider capacity of health systems to manage what are currently manageable conditions.

Public-health responses tend to focus on several fronts at once. Prevention through condoms and education reduces transmission; widespread, accessible testing catches infections early; and prompt, correct treatment limits both complications and onward spread. Crucially, careful stewardship of antibiotics, using the right drug at the right dose only when needed, slows the development of resistance, buying time for existing medicines to remain useful.

Diagnostics and vaccines are part of the longer-term picture. Rapid tests that identify not just the infection but whether it is resistant can help doctors choose an effective treatment first time rather than resorting to broad-spectrum drugs that hasten resistance. Research into vaccines against some sexually transmitted bacteria continues, and any success there would ease pressure on antibiotics by preventing infections rather than treating them.

The Guardian analysis frames the European rise as a signal rather than an isolated event. Regions with strong surveillance often detect trends first, but the underlying drivers, behavioural change, gaps in services and the relentless logic of resistance, are global. What is measured in Europe today can indicate pressures building elsewhere, particularly in places with less testing capacity where infections and resistance may go undetected for longer.

For individuals, the guidance is unchanged and straightforward: barrier protection reduces risk, regular testing is important for anyone who is sexually active with new or multiple partners, and completing prescribed treatment fully matters both for personal recovery and for limiting resistance. None of this is new advice, but the resistance dimension gives it added urgency.

The wider message is that sexually transmitted infections cannot be separated from the antimicrobial resistance crisis they are increasingly bound up with. A rise in cases is a health problem in its own right, but the prospect of infections that no longer respond to treatment is what turns a European trend into a concern shared by health authorities around the world.